This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)
A Single Arm, Open Label Multicentre Extension Study To Evaluate The Effectiveness And Safety Of Ocrelizumab In Patients With Multiple Sclerosis Previously Enrolled In A F. Hoffmann-La Roche Sponsored Ocrelizumab Phase IIIb/IV Clinical Trials
2 other identifiers
interventional
1,055
24 countries
153
Brief Summary
This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3 multiple-sclerosis
Started Jul 2018
Longer than P75 for phase_3 multiple-sclerosis
153 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 25, 2018
CompletedStudy Start
First participant enrolled
July 12, 2018
CompletedFirst Posted
Study publicly available on registry
July 26, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 17, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 17, 2025
CompletedNovember 12, 2025
November 1, 2025
7 years
June 25, 2018
November 11, 2025
Conditions
Outcome Measures
Primary Outcomes (5)
Time to onset of CDP sustained for at least 24 weeks and for at least 48 weeks
Up to 2 Years
Percentage of participants who have confirmed disability improvement (CDI), CDP for at least 24 weeks and for at least 48 weeks yearly and over the duration of the treatment
Up to 2 years
Percentage of participants who have improved, stable or worsened disability compared with baseline
Improved, stable or worsened disability is measured by expanded disability status scale (EDSS) (annually/by epoch and over duration of the study) Stable EDSS is defined as EDSS change +/- 0.5. Worsening is \> 0.5 increase of EDSS, Improvement is \>0.5 decrease of EDSS
Up to 2 years
Mean change from inclusion in parent study in EDSS score over the course of the treatment
Up to 2 years
Time to 20% increase in timed 25-foot walk test (T25FWT)
Time to 20% increase in timed nine-hole peg test (9HPT) sustained for at least 24 weeks and for at least 48 weeks, and proportion of patients achieving a sustained increase assessed yearly and at the end treatment
Up to 2 years
Secondary Outcomes (20)
Time to first protocol-defined event of disease activity
Up to 2 Years
Time to first relapse
Up to 2 Years
Annualized relapse rate
Up to 2 Years
Percentage of participants relapse free, yearly and over the course of the treatment
Up to 2 Years
Percentage of participants with no evidence of protocol-defined disease activity (NEDA) yearly and over the duration of the treatment
Up to 2 Years
- +15 more secondary outcomes
Study Arms (1)
Ocrelizumab
EXPERIMENTALParticipants will receive a single 600-mg infusion of Ocrelizumab every 24 weeks up to Week 72 of this study.
Interventions
Participants will receive a 600-mg infusion of Ocrelizumab every 24 months for two years.
Eligibility Criteria
You may qualify if:
- Signed Informed Consent Form
- Able to comply with the study protocol, in the investigator's judgment
- Completed the treatment period of Roche sponsored ocrelizumab P-trials
You may not qualify if:
- Hypersensitivity to ocrelizumab or to any of its excipients.
- Participantss in a severely immunocompromised state until the condition resolves.
- Evidence of any adverse event potentially attributable to ocrelizumab, for which the local label recommends permanent discontinuation.
- Existence of a contra-indication as per SmPC
- Prohibited concomitant medication as specified in protocol
- Participants intending to become pregnant during the study or within 6 months after the last dose of the study drug in the parent study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (159)
Hospital Churruca Visca
Buenos Aires, C1437JCP, Argentina
Centro de Especialidades Neurológicas y Rehabilitación - CENyR
Ciudad Autonoma Buenos Aires, C1061ABD, Argentina
Fundacion Rosarina de Neurorehabilitacion
Rosario, 2000, Argentina
AZ Sint Jan
Bruges, 8000, Belgium
UZ Antwerpen
Edegem, 2650, Belgium
CHU Tivoli
La Louvière, 7100, Belgium
CHU de Liège (Sart Tilman)
Liège, 4000, Belgium
Revalidatie en MS Centrum
Overpelt, 3900, Belgium
Instituto de Neurologia de Curitiba
Curitiba, Paraná, 81210-310, Brazil
Hospital Sao Lucas - PUCRS
Porto Alegre, Rio Grande do Sul, 90610-000, Brazil
Hospital das Clinicas - FMUSP
São Paulo, São Paulo, 05403-900, Brazil
Shat Np Sveti Naum
Sofia, 1113, Bulgaria
Multiprofile Hosp. for Active Treatment
Sofia, 1309, Bulgaria
University of British Columbia
Vancouver, British Columbia, V6T 1Z4, Canada
London Health Sciences Centre Uni Campus
London, Ontario, N6A 5A5, Canada
The Ottawa Hospital - General Campus
Ottawa, Ontario, K1H 8L6, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5, Canada
Clinique NeuroOutaouais
Gatineau, Quebec, J8Y 1W2, Canada
Recherche Sepmus Inc.
Greenfield Park, Quebec, J4V 2J2, Canada
Montreal Neurological Institute and Hospital
Montreal, Quebec, H3A 2B4, Canada
Clinical Hospital Centre Zagreb
Zagreb, 10000, Croatia
Fakultni nemocnice u sv. Anny
Brno, 656 91, Czechia
Nemocnice Jihlava
Jihlava, 58633, Czechia
VFN Praha Poliklinika Rs Centrum - Budova A
Prague, 12808, Czechia
Fakultni nemocnice v Motole
Prague, 150 06, Czechia
Aalborg Universitetshospital
Aalborg, 9000, Denmark
Aarhus Universitetshospital
Aarhus N, 8200, Denmark
Rigshospitalet Glostrup
Glostrup Municipality, 2600, Denmark
Odense Universitetshospital, Neurologisk Afdeling N
Odense C, 5000, Denmark
Hjerne- og nervesygdomme, Ambulatorium, Skleroseklinikken
Sønderborg, 6400, Denmark
East Tallinn Central Hospital
Tallinn, 10138, Estonia
West Tallinn Central Hospital
Tallinn, 10617, Estonia
Tartu University Hospital
Tartu, 51014, Estonia
Mehiläinen Neo Turku
Turku, 20520, Finland
CHU de Besancon Hopital Jean Minjoz
Besançon, 25030, France
Groupe Hospitalier Pellegrin
Bordeaux, 33076, France
Hopital neurologique Pierre Wertheimer - CHU Lyon
Bron, 69677, France
Hopital Gabriel Montpied CHU de Clermont-Ferrand
Clermont-Ferrand, 63003, France
CH de Gonesse
Gonesse, 95503, France
CHU de Grenoble
La Tronche, 38700, France
Hopital Roger Salengro Service de Neurologie
Lille, 59037, France
CHU de la Timone - Hopital d Adultes
Marseille, 13005, France
Hopital Gui de Chauliac
Montpellier, 34295, France
Hopital Central - CHU de Nancy
Nancy, 54035, France
Hôpital Pasteur
Nice, 06002, France
CHU de Nîmes Hopital Caremeau
Nîmes, 30900, France
Groupe Hospitalier Pitié- Salpétrière
Paris, 75651, France
Hôpital de Poissy
Poissy, 78300, France
CHU de Rouen Hopital
Rouen, 76031, France
Höpital Hautepierre
Strasbourg, 67098, France
HIA de Toulon hôpital militaire
Toulon, 83041, France
Budapesti Jahn Ferenc Dél-pesti Kórház és Rendel?intézet
Budapest, 1204, Hungary
VALEOMED Diagnosztikai Központ
Esztergom, 2500, Hungary
St Vincents University Hospital
Dublin, Ireland
Ospedale SS. Annunziata - Clinica Neurologica - Centro Sclerosi Multipla
Chieti, Abruzzo, 66013, Italy
Ospedale San Salvatore
L’Aquila, Abruzzo, 67100, Italy
IRCCS Ospedale Casa Sollievo Della Sofferenza
San Giovanni Rotondo, Apulia, 71013, Italy
A. O. U. Federico II
Napoli, Campania, 80131, Italy
Università degli Studi della Campania Luigi Vanvitelli
Napoli, Campania, 80131, Italy
Ospedale Bellaria
Bologna, Emilia-Romagna, 40139, Italy
Policlinico Tor Vergata Dip. Neuroscienze-Clinica Neurologica-UOSD Sclerosi Multipla
Rome, Lazio, 00133, Italy
Ospedale S.Camillo Forlanini
Rome, Lazio, 00152, Italy
Policlinico Universitario A. Gemelli
Rome, Lazio, 00168, Italy
Azienda Ospedaliera Sant'Andrea
Rome, Lazio, 00189, Italy
Irccs A.O.U.San Martino Ist
Genoa, Liguria, 16132, Italy
ASST PAPA GIOVANNI XXIII Neurologia USS Malattie Autoimmuni Centro Sclerosi Multipla
Bergamo, Lombardy, 24127, Italy
Ospedale S.Antonio Abate
Gallarate, Lombardy, 21013, Italy
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico
Milan, Lombardy, 20122, Italy
IRCCS Ospedale San Raffaele
Milan, Lombardy, 20132, Italy
Fond. Istituto Neurologico C.Besta
Milan, Lombardy, 20133, Italy
Ospedale Civile di Montichiari
Montichiari, Lombardy, 25018, Italy
IRCCS Istituto Neurologico C. Mondino?Dip. Neurologia Neuroriabilitazione S.S. Sclerosi Multipla
Pavia, Lombardy, 27100, Italy
IRCCS Istituto Neurologico Neuromed
Pozzilli, Molise, 86077, Italy
Ospedale Binaghi
Cagliari, Sardinia, 09126, Italy
AOU Policlinico V. Emanuele - P.O G. Rodolico
Catania, Sicily, 95123, Italy
Fondazione Istituto S. Raffaele - Giglio
Cefalù, Sicily, 90015, Italy
AOU Policlinico Giaccone
Palermo, Sicily, 90129, Italy
AO Ospedali Riuniti Villa Sofia-Cervello
Palermo, Sicily, 90146, Italy
AOU Ospedali Riuniti Umberto I-G.M. Lancisi-G. Salesi
Ancona, The Marches, 60100, Italy
AOU Careggi
Florence, Tuscany, 50134, Italy
AOUC Azienda Ospedaliero-Universitaria Careggi
Florence, Tuscany, 50134, Italy
AOU Senese - Presidio Ospedaliero Le Scotte
Siena, Tuscany, 53100, Italy
AO di Perugia - Ospedale S. Maria della Misericordia
Perugia, Umbria, 06156, Italy
Azienda Ospedaliera di Padova
Padua, Veneto, 35128, Italy
Policlinico G.B. Rossi
Verona, Veneto, 37134, Italy
Ibn Sina Hospital
Kuwait City, 10002, Kuwait
Hospital General de México
Mexico City, Mexico CITY (federal District), 06726, Mexico
Hospital Angeles de Culiacán, Neurociencias Estudios Clínicos SC
Culiacán, Sinaloa, 80020, Mexico
Unidad de investigacion en salud (UIS)
Mexico City, 14050, Mexico
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, 5223 GZ, Netherlands
Amsterdam UMC Location VUMC
Amsterdam, 1081 HV, Netherlands
Amphia Ziekenhuis
Breda, 4819 EV, Netherlands
Groene Hart Ziekenhuis
Gouda, 2803 HH, Netherlands
Maasstadziekenhuis
NL -rotterdam, 3079 DZ, Netherlands
Zuyderland Medisch Centrum - Sittard Geleen
Sittard-Geleen, 6162 BG, Netherlands
Elisabeth-TweeSteden Ziekenhuis
Tilburg, 5022 GC, Netherlands
Haukeland universitetssykehus
Bergen, 5021, Norway
Sykehuset Buskerud HF
Drammen, 3004, Norway
Stavanger Universitetssykehus, Helse Stavanger HF
Stavanger, 4011, Norway
Neurocentrum Bydgoszcz sp. z o.o
Bydgoszcz, 85-796, Poland
COPERNICUS Podmiot Leczniczy Sp. z o. o. Szpital im. M. Kopernika
Gdansk, 80-803, Poland
Care Clinic
Katowice, 40-568, Poland
Malopolskie Centrum Diagnostyczne MEDICAL Sp. z o. o.
Krakow, 31-637, Poland
Centrum Neurologii Krzysztof Selmaj
Lodz, 90-324, Poland
Indywidualna Praktyka Lekarska Prof. Dr Hab. N. Med. Konrad Rejdak.
Lublin, 20-410, Poland
Klinika Neurologii I Wydzialu Lekarskiego WUM w Warszawie
Warsaw, 02-097, Poland
Instytut Psychiatrii i Neurologii II Klinika Neurologiczna
Warsaw, 02-957, Poland
Hospital de Braga
Braga, 4710-243, Portugal
HUC
Coimbra, 3000-075, Portugal
Hospital Beatriz Angelo
Loures, 2674-514, Portugal
Hospital Geral de Santo Antonio
Porto, 4099-001, Portugal
Univerzitna nemocnica Bratislava
Bratislava, 813 69, Slovakia
Univerzitna nemocnica Bratislava Nemocnica Ruzinov
Bratislava, 826 06, Slovakia
Fakultna nemocnica Trnava
Trnava, 917 75, Slovakia
University Medical Centre
Ljubljana, 1000, Slovenia
University Medical Centre Maribor
Maribor, 2000, Slovenia
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Hospital General de Castellon
Castellon, Castellon, 12004, Spain
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, LA Coruna, 15006, Spain
Hospital Universitari Arnau de Vilanova de Lleida
Lleida, Lerida, 25198, Spain
Hospital Quiron de Madrid
Pozuelo de Alarcón, Madrid, 28223, Spain
Complejo Hospitalario Universitario de Vigo - Xeral Cies
Vigo, Pontevedra, 36312, Spain
Hospital Universitario Central de Asturias
Oviedo, Principality of Asturias, Spain
Hospital Vall d'Hebron
Barcelona, 08035, Spain
Hospital Puerta del Mar
Cadiz, 11009, Spain
Hospital Universitari de Girona Dr. Josep Trueta
Girona, 17007, Spain
Universitario de La Princesa
Madrid, 28006, Spain
Hospital Universitario Clínico San Carlos
Madrid, 28040, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Hospital Universitario La Paz
Madrid, 28046, Spain
Hospital Universitario Virgen de Arrixaca
Murcia, Spain
Hospital Clinico Universitario de Valencia
Valencia, 46010, Spain
Hospital Universitario la Fe
Valencia, 46026, Spain
Sahlgrenska Sjukhuset
Gothenburg, 413 45, Sweden
Centralsjukhuset
Karlstad, 65185, Sweden
Centrum för Neurologi
Stockholm, 113 41, Sweden
Hacettepe University Medical Faculty
Ankara, 06100, Turkey (Türkiye)
Gazi University Medical Faculty
Ankara, 06500, Turkey (Türkiye)
Mustafa Kemal Ataturk UTF
Hatay, 31001, Turkey (Türkiye)
Istanbul University Istanbul School of Medicine
Istanbul, 34093, Turkey (Türkiye)
Istanbul Universitesi - Cerrahpasa Cerrahpasa Tip Fakultesi
Istanbul, 34098, Turkey (Türkiye)
Selcuk University Medical Faculty
Konya, 42131, Turkey (Türkiye)
Ondokuz Mayis University School of Medicine
Samsun, 55139, Turkey (Türkiye)
Karadeniz Tecnical Uni. Med. Fac.
Trabzon, 61080, Turkey (Türkiye)
Royal Devon and Exeter Hospital (Wonford)
Exeter, EX2 5DW, United Kingdom
Queen Elizabeth University Hospital
Glasgow, G51 4TF, United Kingdom
Raigmore Hospital
Inverness, IV2 3UV, United Kingdom
Leeds Teaching Hospitals NHS Trust
Leeds, LS9 7AU, United Kingdom
The Royal London Hospital
London, E1 1BB, United Kingdom
Royal Free Hospital
London, NW3 2QS, United Kingdom
Kings College Hospital
London, SE5 9RS, United Kingdom
St George's Hospital
London, SW17 0QT, United Kingdom
Charing Cross Hospital
London, W6 8RF, United Kingdom
National Hospital for Neurology and Neurosurgery,
London, WC1 3BG, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP, United Kingdom
Salford Royal NHS Foundation Trust
Salford, M6 8HD, United Kingdom
Royal Hallamshire Hospita
Sheffield, S10 2JF, United Kingdom
Morriston Hospital
Swansea, SA6 6NL, United Kingdom
Royal Cornwall Hospital
Truro, TR1 3LQ, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Trials
Hoffmann-La Roche
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 25, 2018
First Posted
July 26, 2018
Study Start
July 12, 2018
Primary Completion
July 17, 2025
Study Completion
July 17, 2025
Last Updated
November 12, 2025
Record last verified: 2025-11
Data Sharing
- IPD Sharing
- Will share
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing